Hims & Hers Rises with Eli Lilly‑Based New Obesity Approach

Hims & Hers (HIMS) announced a new strategy focused on obesity treatment, leveraging its telehealth platform in partnership with Eli Lilly (LLY). Under the collaboration, the company plans to offer Lilly’s obesity drugs, including GLP‑1 agonists such as tirzepatide, to its customer base. The high demand for Lilly’s obesity medications, particularly tirzepatide, positions Hims & Hers to diversify its revenue streams and broaden its product portfolio. The strategic partnership is expected to support the company’s growth objectives, with investors anticipating increased earnings forecasts and a positive impact on market performance. However, the commercialization process will need to address regulatory and supply‑chain risks. While the move could create a competitive advantage in the sector, effective risk management will be critical. This is not investment advice.